Related Experiment Videos
Discontinuing antidepressant treatment in major depression
A C Viguera1, R J Baldessarini, J Friedberg
1Consolidated Department of Psychiatry, Harvard Medical School, Boston, Mass., USA.
Harvard Review of Psychiatry
|April 29, 1998
Summary
Continuing antidepressant medication significantly reduces major depression relapse risk compared to discontinuation. This is crucial for managing depression and preventing recurrence, especially for those with a history of multiple episodes.
Area of Science:
- Psychiatry
- Clinical Psychology
- Pharmacology
Background:
- Maintenance treatments for bipolar disorder and schizophrenia are established.
- Discontinuation of these treatments carries a high risk of relapse.
- Long-term antidepressant benefits and discontinuation risks in major depression are less defined.
Purpose of the Study:
- To evaluate the risks and benefits of long-term antidepressant treatment in major depression.
- To compare relapse rates between continued antidepressant treatment and discontinuation after recovery.
Main Methods:
- A meta-analysis of 27 studies involving 3037 patients with major depression.
- Patients were treated with antidepressants for an average of 5.78 months, then followed for 16.6 months.
- Data compared relapse rates for continued treatment versus discontinued antidepressant medication.
Main Results:
- Continued antidepressant treatment showed significantly lower monthly relapse rates (1.85% vs. 6.24%) and 12-month relapse risk (19.5% vs. 44.8%).
- Time to 50% relapse was substantially longer with continued treatment (48.0 vs. 14.2 months).
- Gradual discontinuation did not reduce relapse rates; higher prior illness burden increased relapse risk after discontinuation.
Conclusions:
- Long-term antidepressant treatment is associated with significantly lower relapse rates in major depression.
- Patients with a history of multiple depressive episodes are at higher risk of relapse upon discontinuation.
- Continued antidepressant therapy is vital for preventing relapse, particularly in vulnerable patient groups.